biosimilars market

Alvotech (NASDAQ: ALVO) will hold its 2025 Annual General Meeting on June 25 in Reykjavik, with virtual access available. Shareholders will review governance updates, financial results, and strategies to bolster its position in the biosimilars market, projected to yield $50 billion in global savings by 2027. Key discussions include expanding its biosimilar pipeline, regulatory progress in the U.S. and Europe, and addressing pricing challenges and patent cliffs. Analysts highlight priorities like commercial partnerships, scalable manufacturing, and differentiation in immunology and oncology. The meeting may signal strategic shifts as Alvotech navigates evolving FDA regulations and leverages biosimilars to counter pharmaceutical revenue declines, emphasizing speed-to-market and cost efficiency.